Stock Research: ANI Pharma

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

ANI Pharma

NasdaqGM:ANIP US00182C1036
84
  • Value
    27
  • Growth
    75
  • Safety
    Safety
    84
  • Combined
    75
  • Sentiment
    86
  • 360° View
    360° View
    84
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

ANI Pharmaceuticals, Inc. is a biopharmaceutical company that develops, manufactures, and commercializes therapeutics. It operates in the biopharmaceutical industry, with a focus on rare disease conditions and branded pharmaceutical products. The company's operations are primarily within the United States. In the last fiscal year, the company had a market cap of $1,379 million, profits of $364 million, and revenue of $614 million, with 897 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 84 (better than 84% compared with alternatives) for 2025, overall professional sentiment and financial characteristics for the stock ANI Pharma are very positive. The 360° View is based on consolidating four consolidated indicators, with all but one indicator above average for ANI Pharma. The consolidated Value Rank has an attractive rank of 84, which means that the share price of ANI Pharma is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 84% of alternative stocks in the same industry. The consolidated Growth Rank has a good rank of 75, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. In addition, professional market sentiment is above average compared with other stock investment alternatives with a Sentiment Rank of 86. But the company’s financing is risky with a Safety rank of 27. This means 73% of comparable companies have a safer financing structure than ANI Pharma. ...read more

more
Index
NASDAQ
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 2-Oct-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
84 53 42 61
Growth
75 59 79 85
Safety
Safety
27 69 55 36
Sentiment
86 80 96 34
360° View
360° View
84 88 93 60
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
91 83 76 17
Opinions Change
94 50 83 92
Pro Holdings
n/a 36 74 49
Market Pulse
57 91 48 30
Sentiment
86 80 96 34
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
84 53 42 61
Growth
75 59 79 85
Safety Safety
27 69 55 36
Combined
75 76 73 73
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
64 70 68 87
Price vs. Earnings (P/E)
45 55 44 56
Price vs. Book (P/B)
32 42 39 46
Dividend Yield
86 1 1 1
Value
84 53 42 61
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
63 83 41 77
Profit Growth
64 53 98 35
Capital Growth
38 30 37 59
Stock Returns
87 49 77 91
Growth
75 59 79 85
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
23 47 38 40
Refinancing
51 63 77 41
Liquidity
38 57 40 44
Safety Safety
27 69 55 36

Similar Stocks

Discover high‑ranked alternatives to ANI Pharma and broaden your portfolio horizons.

Meta

NasdaqGS:FB
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Intuit

NasdaqGS:INTU
Country: USA
Industry: Application Software
Size: X-Large
Full Stock Analysis

Lithia Motors

NYSE:LAD
Country: USA
Industry: Automotive Retail
Size: X-Large
Full Stock Analysis

Micron

NasdaqGS:MU
Country: USA
Industry: Semiconductors
Size: X-Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.